首页VRX • SWX
add
Valeant製藥國際公司
市场资讯
财务信息
损益表
收入
净收入
(USD) | 2024年9月info | 年同比变化 |
---|---|---|
收入 | 25.10亿 | 12.15% |
经营支出 | 12.70亿 | 13.29% |
净收入 | -8500.00万 | 77.51% |
净利润率 | -3.39 | 79.93% |
每股收益 | 1.12 | 9.34% |
息税折旧摊销前利润 | 8.66亿 | 8.93% |
有效税率 | -338.10% | — |
资产负债表
总资产
负债总额
(USD) | 2024年9月info | 年同比变化 |
---|---|---|
现金及短期投资 | 7.19亿 | -5.39% |
总资产 | 265.40亿 | -1.94% |
负债总额 | 267.82亿 | -1.89% |
权益总额 | -2.42亿 | — |
发行在外的股份 | 3.68亿 | — |
市净率 | -6.72 | — |
资产回报率 | 5.13% | — |
资本回报率 | 6.37% | — |
现金流
现金净变动
(USD) | 2024年9月info | 年同比变化 |
---|---|---|
净收入 | -8500.00万 | 77.51% |
来自运营的现金 | 4.05亿 | 43.62% |
投资现金 | -1.02亿 | 94.60% |
融资现金 | -1.89亿 | -110.41% |
现金净变动 | 1.27亿 | -33.85% |
自由现金流 | 6.07亿 | 261.43% |
简介
Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.
Valeant was originally founded in 1959, as ICN Pharmaceuticals by Milan Panić in California. During the 2010s, Valeant adopted a strategy of buying up other pharmaceutical companies which manufactured effective medications for a variety of medical problems, and then increasing the price of those medications. As a result, the company grew rapidly and in 2015 was the most valuable company in Canada.
Valeant was involved in a number of controversies surrounding drug price hikes and the use of a specialty pharmacy for the distribution of its drugs. This led to an investigation by the U.S. Wikipedia
CEO
成立时间
1959
员工数量
20,270